Egypt - Catalyst Developments plans to deliver five administrative and commercial projects worth EGP 4.5 billion in New Cairo during 2021, Daily News cited Chairperson Moataz Abdel Shafi on May 3rd.

Abdel Shafi noted that the company injected EGP 325 million investments in construction works in 2020.

He further noted that the company has a total portfolio of five administrative, commercial, and medical projects in New Cairo.

He added that the company studies investing up to EGP 3 billion in launching a new administrative offices project during the fourth quarter of 2021, in addition to other projects in 2022.

Abdel Shafi pointed out that the implementation rate at the Cairo Capital Center (CCC) project has reached 95%, noting that the project will be fully delivered in June.

As regards the two North Plus projects, the external and internal finishes, electricity, air conditioning, and fire networks, as well as all services for the project have been completed.

The trial operation of the project has begun, with distinctive brands being utilized in this regard.

As for Elegantry project, the units have been handed over to clients, and that the administrative and medical part of the project will be delivered and start operating in June 2021.

On the Business Plus project, all concrete works have been completed.

The Chairperson said that the first and second phases of the company’s Ozone project in New Cairo will be delivered in 2021.

Catalyst Developments’ total sales of its entire projects reached 86%.

 

Copyright © 2021 Arab Finance Brokerage Company All rights reserved. Provided by SyndiGate Media Inc. (Syndigate.info).

Disclaimer: The content of this article is syndicated or provided to this website from an external third party provider. We are not responsible for, and do not control, such external websites, entities, applications or media publishers. The body of the text is provided on an “as is” and “as available” basis and has not been edited in any way. Neither we nor our affiliates guarantee the accuracy of or endorse the views or opinions expressed in this article. Read our full disclaimer policy here.